The transaction represents Haemonetics’s third blood management-related acquisition in 2007.
Chris Lindop, CFO of Haemonetics, said: “The TEG business acquisition is strategic and strengthens our vision of being a global leader in blood management for our customers. The business expands Haemonetics’s product portfolio by providing clinicians with a diagnostic tool to optimize blood management practice.”